schliessen

Filtern

 

Bibliotheken

The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy

BACKGROUND: A study was undertaken to investigate the effect of baseline renal function on treatment outcome in patients treated with vascular endothelial growth factor (VEGF)-targeted therapy for metastatic renal cell carcinoma (mRCC).METHODS: Retrospective data from 6 North American cancer centers... Full description

Journal Title: Cancer 15 January 2012, Vol.118(2), pp.365-370
Main Author: Macfarlane, Robyn
Other Authors: Heng, Daniel Y. C. , Xie, Wanling , Knox, Jennifer J. , Mcdermott, David F. , Rini, Brian I. , Kollmannsberger, Christian , Choueiri, Toni K.
Format: Electronic Article Electronic Article
Language: English
Subjects:
ID: ISSN: 0008-543X ; E-ISSN: 1097-0142 ; DOI: 10.1002/cncr.26201
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: wj10.1002/cncr.26201
title: The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy
format: Article
creator:
  • Macfarlane, Robyn
  • Heng, Daniel Y. C.
  • Xie, Wanling
  • Knox, Jennifer J.
  • Mcdermott, David F.
  • Rini, Brian I.
  • Kollmannsberger, Christian
  • Choueiri, Toni K.
subjects:
  • Metastatic Renal Cell Carcinoma
  • Sunitinib
  • Bevacizumab
  • Sorafenib
  • Renal Function
  • Glomerular Filtration Rate
ispartof: Cancer, 15 January 2012, Vol.118(2), pp.365-370
description: BACKGROUND: A study was undertaken to investigate the effect of baseline renal function on treatment outcome in patients treated with vascular endothelial growth factor (VEGF)-targeted therapy for metastatic renal cell carcinoma (mRCC).METHODS: Retrospective data from 6 North American cancer centers (3 US and 3 Canadian) were pooled to identify patients with mRCC treated with VEGF-targeted therapy. Patient characteristics, response rate, time to treatment failure, and overall survival were collected. The Modification of Diet in Renal Disease formula was used at therapy initiation for calculation of glomerular filtration rate (GFR).RESULTS: Five hundred twenty-nine patients with mRCC who received sunitinib (n = 323), sorafenib (n = 165), or bevacizumab (n = 41) were included in this analysis. Patient characteristics included: 74% male, median age 61 years, and median GFR 60.1 mL/min/1.73 m(2) (range, 6.5-174.2). On univariate analysis, patients with a GFR
language: eng
source:
identifier: ISSN: 0008-543X ; E-ISSN: 1097-0142 ; DOI: 10.1002/cncr.26201
fulltext: fulltext
issn:
  • 0008-543X
  • 0008543X
  • 1097-0142
  • 10970142
url: Link


@attributes
ID608771482
RANK0.06999999
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
LOCALfalse
PrimoNMBib
record
control
sourcerecordid10.1002/cncr.26201
sourceidwj
recordidTN_wj10.1002/cncr.26201
sourcesystemPC
pqid914668354
galeid278109587
display
typearticle
titleThe impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy
creatorMacfarlane, Robyn ; Heng, Daniel Y. C. ; Xie, Wanling ; Knox, Jennifer J. ; Mcdermott, David F. ; Rini, Brian I. ; Kollmannsberger, Christian ; Choueiri, Toni K.
ispartofCancer, 15 January 2012, Vol.118(2), pp.365-370
identifier
subjectMetastatic Renal Cell Carcinoma ; Sunitinib ; Bevacizumab ; Sorafenib ; Renal Function ; Glomerular Filtration Rate
languageeng
source
descriptionBACKGROUND: A study was undertaken to investigate the effect of baseline renal function on treatment outcome in patients treated with vascular endothelial growth factor (VEGF)-targeted therapy for metastatic renal cell carcinoma (mRCC).METHODS: Retrospective data from 6 North American cancer centers (3 US and 3 Canadian) were pooled to identify patients with mRCC treated with VEGF-targeted therapy. Patient characteristics, response rate, time to treatment failure, and overall survival were collected. The Modification of Diet in Renal Disease formula was used at therapy initiation for calculation of glomerular filtration rate (GFR).RESULTS: Five hundred twenty-nine patients with mRCC who received sunitinib (n = 323), sorafenib (n = 165), or bevacizumab (n = 41) were included in this analysis. Patient characteristics included: 74% male, median age 61 years, and median GFR 60.1 mL/min/1.73 m(2) (range, 6.5-174.2). On univariate analysis, patients with a GFR <60 (n = 262) were more likely to have had a previous nephrectomy (P < .0001) and to be older (P < .0001), but were less likely to have poor prognostic features such as anemia (P = .041), hypercalcemia (P = .008), neutrophilia (P = .039), thrombocytosis (P < .0001), short diagnosis to treatment interval (P = .007), and low Karnofsky performance status (P = .051). GFR <60, when adjusted for poor risk factors, did not have an impact on type of objective response (odds ratio, 1.31; 95% confidence interval [CI], 0.74-2.32; P = .359), time to treatment failure (hazard ratio [HR], 0.97; 95% CI, 0.79-1.19; P = .772), or overall survival (HR, 0.90; 95% CI, 0.69-1.17; P = .439).CONCLUSIONS: Renal function at therapy initiation does not adversely affect the efficacy of VEGF-targeted therapy in mRCC. Clinicians should not avoid treating patients with impaired baseline renal function.
version6
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
search
creatorcontrib
0Macfarlane, Robyn
1Heng, Daniel Y. C.
2Xie, Wanling
3Knox, Jennifer J.
4Mcdermott, David F.
5Rini, Brian I.
6Kollmannsberger, Christian
7Choueiri, Toni K.
titleThe impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy
subject
0Metastatic Renal Cell Carcinoma
1Sunitinib
2Bevacizumab
3Sorafenib
4Renal Function
5Glomerular Filtration Rate
general
0English
1Wiley Subscription Services, Inc., A Wiley Company
210.1002/cncr.26201
3Wiley Online Library
sourceidwj
recordidwj10.1002/cncr.26201
issn
00008-543X
10008543X
21097-0142
310970142
rsrctypearticle
creationdate2012
addtitleCancer
searchscope
0wj
1wiley
scope
0wj
1wiley
lsr30VSR-Enriched:[galeid, description, pages, pqid]
sort
titleThe impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy
authorMacfarlane, Robyn ; Heng, Daniel Y. C. ; Xie, Wanling ; Knox, Jennifer J. ; Mcdermott, David F. ; Rini, Brian I. ; Kollmannsberger, Christian ; Choueiri, Toni K.
creationdate20120115
facets
frbrgroupid-86513901499354360
frbrtype5
languageeng
creationdate2012
topic
0Metastatic Renal Cell Carcinoma
1Sunitinib
2Bevacizumab
3Sorafenib
4Renal Function
5Glomerular Filtration Rate
collectionWiley Online Library
prefilterarticles
rsrctypearticles
creatorcontrib
0Macfarlane, Robyn
1Heng, Daniel Y. C.
2Xie, Wanling
3Knox, Jennifer J.
4Mcdermott, David F.
5Rini, Brian I.
6Kollmannsberger, Christian
7Choueiri, Toni K.
jtitleCancer
toplevelpeer_reviewed
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
aulast
0Macfarlane
1Heng
2Xie
3Knox
4McDermott
5Rini
6Kollmannsberger
7Choueiri
aufirst
0Robyn
1Daniel Y. C.
2Wanling
3Jennifer J.
4David F.
5Brian I.
6Christian
7Toni K.
au
0Macfarlane, Robyn
1Heng, Daniel Y. C.
2Xie, Wanling
3Knox, Jennifer J.
4Mcdermott, David F.
5Rini, Brian I.
6Kollmannsberger, Christian
7Choueiri, Toni K.
atitleThe impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor‐targeted therapy
jtitleCancer
risdate20120115
volume118
issue2
spage365
epage370
issn0008-543X
eissn1097-0142
genrearticle
ristypeJOUR
copHoboken
pubWiley Subscription Services, Inc., A Wiley Company
doi10.1002/cncr.26201
pages365-370
date2012-01-15